dr zafar semaglutide M. Zafar, MD, SC dr zafar semaglutide Dr. Zafar

The difference between topical and injectable is not a marginal efficiency gain

In a randomized, double-blind, placebo-controlled study in humans, it was determined that repeated doses of a combination therapy with NR and PTER increased NAD + levels safely and effectively (Dellinger et al., 2017)

IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

In medical school, were taught that the US diet is plenty good enough to prevent any vitamin deficiencies

Asymptomatic gallstones do not automatically prevent semaglutide therapy, but symptomatic disease requires medical evaluation first